AEON Biopharma Statistics
Share Statistics
AEON Biopharma has 39.97M shares outstanding. The number of shares has increased by 7.56% in one year.
| Shares Outstanding | 39.97M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.55M |
| Failed to Deliver (FTD) Shares | 22.30K |
| FTD / Avg. Volume | 1.29% |
Short Selling Information
The latest short interest is 164.26K, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 164.26K |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.94% |
| Short Ratio (days to cover) | 1.6 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.09.
| PE Ratio | 0 |
| Forward PE | -1.09 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for AEON Biopharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48, with a Debt / Equity ratio of 0.
| Current Ratio | 0.48 |
| Quick Ratio | 0.48 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is null% and return on capital (ROIC) is 31.6%.
| Return on Equity (ROE) | null% |
| Return on Assets (ROA) | null% |
| Return on Capital (ROIC) | 31.6% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -10.51M |
| Employee Count | 5 |
| Asset Turnover | null |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -160.49K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -96.9% in the last 52 weeks. The beta is 0.4, so AEON Biopharma 's price volatility has been higher than the market average.
| Beta | 0.4 |
| 52-Week Price Change | -96.9% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 2.05 |
| Relative Strength Index (RSI) | 23.45 |
| Average Volume (20 Days) | 1.73M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -48.43M |
| Net Income | -52.56M |
| EBITDA | -48.36M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 5.16M in cash and 278.00K in debt, giving a net cash position of 4.88M.
| Cash & Cash Equivalents | 5.16M |
| Total Debt | 278.00K |
| Net Cash | 4.88M |
| Retained Earnings | -473.60M |
| Total Assets | 4.00M |
| Working Capital | -8.36M |
Cash Flow
In the last 12 months, operating cash flow was -35.58M and capital expenditures -306.00K, giving a free cash flow of -35.89M.
| Operating Cash Flow | -35.58M |
| Capital Expenditures | -306.00K |
| Free Cash Flow | -35.89M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AEON does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -411.7% |
Analyst Forecast
The average price target for AEON is $5, which is 2172.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 2172.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -183.79 |
| Piotroski F-Score | 5 |